Zelira Therapeutics Limited (ZLD.AX)
AUD 0.39
(-4.88%)
AUD 0.39
(-4.88%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -36.44 Million AUD | -430.62% |
| 2023 | -6.86 Million AUD | 46.46% |
| 2022 | -12.82 Million AUD | -39.75% |
| 2021 | -9.17 Million AUD | -21.34% |
| 2020 | -7.7 Million AUD | -78.93% |
| 2019 | -251.28 Thousand AUD | -50.13% |
| 2018 | 635.4 Thousand AUD | -9.54% |
| 2017 | -3.71 Million AUD | -193.28% |
| 2016 | -898.64 Thousand AUD | -106.79% |
| 2015 | -423.82 Thousand AUD | -43.75% |
| 2014 | -289.88 Thousand AUD | 6.94% |
| 2013 | -306.62 Thousand AUD | 48.62% |
| 2012 | -624 Thousand AUD | -36.57% |
| 2011 | 18.57 Thousand AUD | 32.57% |
| 2010 | -1.09 Million AUD | 56.27% |
| 2009 | -20.21 Million AUD | -213.74% |
| 2008 | -487.99 Thousand AUD | 97.55% |
| 2007 | -34.88 Million AUD | -1533.89% |
| 2006 | -1.22 Million AUD | -420.31% |
| 2005 | -402.81 Thousand AUD | -16231.77% |
| 2004 | 1454.00 AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | -2.63 Million AUD | 0.0% |
| 2024 Q2 | -3.06 Million AUD | 0.0% |
| 2024 FY | - AUD | 17.09% |
| 2023 Q4 | -3.64 Million AUD | 0.0% |
| 2023 FY | - AUD | 46.46% |
| 2023 Q2 | -3.22 Million AUD | 0.0% |
| 2022 FY | - AUD | -39.75% |
| 2022 Q2 | -4.96 Million AUD | 0.0% |
| 2022 Q4 | -7.86 Million AUD | 0.0% |
| 2021 Q2 | -4.81 Million AUD | 0.0% |
| 2021 FY | - AUD | -21.34% |
| 2021 Q4 | -4.36 Million AUD | 0.0% |
| 2020 Q4 | -7.5 Million AUD | 0.0% |
| 2020 Q2 | 724.88 Thousand AUD | 0.0% |
| 2020 FY | - AUD | -78.93% |
| 2019 Q4 | -2.32 Million AUD | 0.0% |
| 2019 FY | - AUD | -50.13% |
| 2019 Q2 | -240.38 Thousand AUD | 0.0% |
| 2018 Q4 | -58.14 Thousand AUD | 0.0% |
| 2018 FY | - AUD | -9.54% |
| 2018 Q2 | 693.55 Thousand AUD | 0.0% |
| 2017 FY | - AUD | -193.28% |
| 2017 Q4 | -20.06 Thousand AUD | 0.0% |
| 2017 Q2 | -3.69 Million AUD | 0.0% |
| 2016 Q4 | -108.44 Thousand AUD | 51.73% |
| 2016 Q1 | -100.02 Thousand AUD | 0.0% |
| 2016 Q2 | 234.00 AUD | 100.23% |
| 2016 Q3 | -224.65 Thousand AUD | -96108.23% |
| 2016 FY | - AUD | -106.79% |
| 2015 Q3 | -100.02 Thousand AUD | 0.0% |
| 2015 Q1 | -72.47 Thousand AUD | 0.0% |
| 2015 Q4 | -100.02 Thousand AUD | 0.0% |
| 2015 Q2 | -100.02 Thousand AUD | -38.02% |
| 2015 FY | - AUD | -43.75% |
| 2014 Q1 | -76.65 Thousand AUD | 0.0% |
| 2014 Q2 | -72.47 Thousand AUD | 5.46% |
| 2014 Q3 | -72.47 Thousand AUD | 0.0% |
| 2014 Q4 | -72.47 Thousand AUD | 0.0% |
| 2014 FY | - AUD | 6.94% |
| 2013 Q3 | -76.65 Thousand AUD | 0.0% |
| 2013 Q1 | -156 Thousand AUD | 0.0% |
| 2013 Q2 | -76.65 Thousand AUD | 50.86% |
| 2013 FY | - AUD | 48.62% |
| 2013 Q4 | -76.65 Thousand AUD | 0.0% |
| 2012 FY | - AUD | -36.57% |
| 2012 Q3 | -156 Thousand AUD | 0.0% |
| 2012 Q2 | -156 Thousand AUD | -3460.47% |
| 2012 Q1 | 4642.25 AUD | 0.0% |
| 2012 Q4 | -156 Thousand AUD | 0.0% |
| 2011 Q4 | 4642.25 AUD | 0.0% |
| 2011 Q3 | 4642.25 AUD | 0.0% |
| 2011 FY | - AUD | 32.57% |
| 2011 Q2 | 4642.25 AUD | 101.11% |
| 2011 Q1 | -417.75 Thousand AUD | 0.0% |
| 2010 Q4 | -417.75 Thousand AUD | 0.0% |
| 2010 Q3 | -417.75 Thousand AUD | 0.0% |
| 2010 FY | - AUD | 56.27% |
| 2010 Q2 | -417.75 Thousand AUD | 91.74% |
| 2010 Q1 | -5.05 Million AUD | 0.0% |
| 2009 Q2 | -5.05 Million AUD | -260.29% |
| 2009 Q1 | 3.15 Million AUD | 0.0% |
| 2009 Q4 | -5.05 Million AUD | 0.0% |
| 2009 FY | - AUD | -213.74% |
| 2009 Q3 | -5.05 Million AUD | 0.0% |
| 2008 FY | - AUD | 97.55% |
| 2008 Q4 | 3.15 Million AUD | 0.0% |
| 2008 Q3 | 3.15 Million AUD | 0.0% |
| 2008 Q1 | -8.72 Million AUD | 0.0% |
| 2008 Q2 | 3.15 Million AUD | 136.14% |
| 2007 FY | - AUD | -1533.89% |
| 2007 Q1 | -305.1 Thousand AUD | 0.0% |
| 2007 Q2 | -8.72 Million AUD | -2760.3% |
| 2007 Q3 | -8.72 Million AUD | 0.0% |
| 2007 Q4 | -8.72 Million AUD | 0.0% |
| 2006 FY | - AUD | -420.31% |
| 2006 Q2 | -305.1 Thousand AUD | -123.43% |
| 2006 Q3 | -305.1 Thousand AUD | 0.0% |
| 2006 Q1 | -136.55 Thousand AUD | 0.0% |
| 2006 Q4 | -305.1 Thousand AUD | 0.0% |
| 2005 Q2 | -136.55 Thousand AUD | 16.07% |
| 2005 Q1 | -162.7 Thousand AUD | 0.0% |
| 2005 Q4 | -136.55 Thousand AUD | 0.0% |
| 2005 Q3 | -136.55 Thousand AUD | 0.0% |
| 2005 FY | - AUD | -16231.77% |
| 2004 Q4 | -162.7 Thousand AUD | 0.0% |
| 2004 FY | - AUD | 0.0% |
| 2004 Q3 | -162.7 Thousand AUD | 0.0% |
| 2004 Q2 | -162.7 Thousand AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AdAlta Limited | -5.3 Million AUD | -587.219% |
| Acrux Limited | -7.93 Million AUD | -359.478% |
| Race Oncology Limited | -14.2 Million AUD | -156.567% |
| Biome Australia Limited | -1.57 Million AUD | -2208.96% |
| Botanix Pharmaceuticals Limited | -13.91 Million AUD | -161.802% |
| BTC Health Limited | 1.05 Million AUD | 3553.201% |
| Chimeric Therapeutics Limited | -11.29 Million AUD | -222.495% |
| CSL Limited | 4.73 Billion AUD | 100.77% |
| Clarity Pharmaceuticals Ltd | -44.64 Million AUD | 18.38% |
| Clinuvel Pharmaceuticals Limited | 51.86 Million AUD | 170.264% |
| EZZ Life Science Holdings Limited | 10.37 Million AUD | 451.224% |
| Hexima Limited | -995.54 Thousand AUD | -3560.433% |
| Immutep Limited | -42.87 Million AUD | 15.006% |
| Memphasys Limited | -3.3 Million AUD | -1001.701% |
| Neuren Pharmaceuticals Limited | 199.26 Million AUD | 118.288% |
| Noxopharm Limited | -5.94 Million AUD | -512.921% |
| Prescient Therapeutics Limited | -7.18 Million AUD | -407.135% |
| Radiopharm Theranostics Limited | -45.37 Million AUD | 19.691% |
| Starpharma Holdings Limited | -12.57 Million AUD | -189.745% |
| Tissue Repair Ltd | -5.77 Million AUD | -531.017% |
| Biotron Limited | -5.04 Million AUD | -623.032% |
| Alterity Therapeutics Limited | -19.57 Million AUD | -86.194% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -2401.688% |
| Bio-Gene Technology Limited | -2.97 Million AUD | -1124.919% |
| Patrys Limited | -3.49 Million AUD | -943.516% |
| Orthocell Limited | -11.68 Million AUD | -211.967% |
| Imugene Limited | -147.97 Million AUD | 75.374% |
| PYC Therapeutics Limited | -38.11 Million AUD | 4.398% |
| Proteomics International Laboratories Limited | -7.88 Million AUD | -362.022% |
| Cynata Therapeutics Limited | -9.95 Million AUD | -266.236% |
| Arovella Therapeutics Limited | -8.83 Million AUD | -312.55% |
| Nanollose Limited | -1.14 Million AUD | -3074.593% |
| Invex Therapeutics Ltd | -720.44 Thousand AUD | -4958.177% |
| NeuroScientific Biopharmaceuticals Limited | -1.79 Million AUD | -1928.697% |
| Amplia Therapeutics Limited | -4.55 Million AUD | -699.219% |
| Island Pharmaceuticals Limited | -2.81 Million AUD | -1193.104% |
| Nyrada Inc. | -4.59 Million AUD | -692.854% |
| Telix Pharmaceuticals Limited | 22.96 Million AUD | 258.674% |
| Dimerix Limited | -24.95 Million AUD | -46.007% |
| PharmAust Limited | -9.45 Million AUD | -285.551% |
| AnteoTech Limited | -11.57 Million AUD | -214.936% |
| Paradigm Biopharmaceuticals Limited | -64.53 Million AUD | 43.536% |
| Recce Pharmaceuticals Ltd | -21.35 Million AUD | -70.652% |
| Avecho Biotechnology Limited | -3.24 Million AUD | -1023.857% |
| Actinogen Medical Limited | -12.92 Million AUD | -182.027% |
| Immuron Limited | -6.19 Million AUD | -488.486% |
| Argenica Therapeutics Limited | -1.89 Million AUD | -1820.392% |